Purpose: The aims of this study were to compare dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) with diffusion-weighted imaging (DWI) with apparent diffusion coefficient mapping as a stand-alone parameter without any other supportive sequence for breast cancer detection and to assess its combination as multiparametric MRI (mpMRI) of the breast. Materials and Methods: In this institutional review board-approved singlecenter study, prospectively acquired data of 106 patients who underwent breast MRI from 12/2010 to 09/2014 for an imaging abnormality (Breast Imaging Reporting and Data System 0, 4/5) were retrospectively analyzed. Four readers independently assessed DWI and DCE as well as combined as mpMRI. Breast Imaging Reporting and Data System categories, lesion size, and mean apparent diffusion coefficient values were recorded. Histopathology was used as the gold standard. Appropriate statistical tests were used to compare diagnostic values. Results: There were 69 malignant and 41 benign tumors in 106 patients. Four patients presented with bilateral lesions. Dynamic contrast-enhanced MRI was the most sensitive test for breast cancer detection, with an average sensitivity of 100%. Diffusion-weighted imaging alone was less sensitive (82%; P < 0.001) but more specific than DCE-MRI (86.8% vs 76.6%; P = 0.002). Diagnostic accuracy was 83.7% for DWI and 90.6% for DCE-MRI. Multiparametric MRI achieved a sensitivity of 96.8%, not statistically different from DCE-MRI (P = 0.12) and with a similar specificity as DWI (83.8%; P = 0.195), maximizing diagnostic accuracy to 91.9%. There was almost perfect interreader agreement for DWI (κ = 0.864) and DCE-MRI (κ = 0.875) for differentiation of benign and malignant lesions. Conclusion: Dynamic contrast-enhanced MRI is most sensitive for breast cancer detection and thus still indispensable. Multiparametric MRI using DCE-MRI and DWI maintains a high sensitivity, increases specificity, and maximizes diagnostic accuracy, often preventing unnecessary breast biopsies. Diffusion-weighted imaging should not be used as a stand-alone parameter because it detects significantly fewer cancers in comparison with DCE-MRI and mpMRI. 1,2 With the recent controversy and the concerns about the safety of about gadolinium containing contrast agents, 3 the recommendations are that "gadolinium based contrast agents should only be administered if the information so provided is necessary, and specifically expected to increase the confidence in correct disease diagnosis or assessment thereof, or disease exclusion."
D
ynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) is the backbone of any breast MRI imaging protocol and the most sensitive imaging test for breast cancer detection. 1, 2 With the recent controversy and the concerns about the safety of about gadolinium containing contrast agents, 3 the recommendations are that "gadolinium based contrast agents should only be administered if the information so provided is necessary, and specifically expected to increase the confidence in correct disease diagnosis or assessment thereof, or disease exclusion." 4 Several unenhanced MRI parameters spanning the spectrum from diffusion-weighted imaging (DWI) to sodium imaging [5] [6] [7] have been explored to detect breast cancer, with encouraging results. Of all these MRI parameters, DWI has emerged as the most robust and reliable for routine clinical use. With significant advances in hardware and sequence technology such as the use of higher field strengths and readoutsegmented DWI sequences, sensitivities of DWI using apparent diffusion coefficient (ADC) mapping of up to 96% for breast cancer detection and specificities of up to 100% for breast tumor characterization have been reported. 6, [8] [9] [10] [11] It has therefore been suggested that unenhanced imaging with DWI might replace DCE-MRI in for breast cancer detection. [12] [13] [14] [15] [16] However, it must be stressed that most of the studies used a combination of either DCE-MRI, unenhanced T1-weighted, and/or T2-weighted imaging with DWI. 12, [14] [15] [16] [17] [18] [19] [20] [21] In this setting, DWI was not used as a single stand-alone parameter and the potentials of unenhanced DWI may therefore be overestimated. In contrast, several authors have investigated the combined use of DWI and DCE-MRI, which is defined as multiparametric MRI (mpMRI), for improved breast lesion detection and characterization with excellent results. [22] [23] [24] [25] Therefore, the primary goal of this study was to clarify whether DWI without any other supportive sequence achieves a sensitivity equal to that with DCE-MRI for breast cancer detection and thus can be used as a stand-alone parameter. As a secondary goal, we aimed to prove that as both DCE-MRI and DWI have their individual limitations, the best approach for reliable breast cancer diagnosis while avoiding unnecessary breast biopsies is their combination as mpMRI.
MATERIALS AND METHODS
In this institutional review board-approved single-institution study at Medical University of Vienna, prospectively acquired data, where all patients gave written, informed consent, were retrospectively analyzed.
Patients
A prospectively populated research database was searched for patients who underwent state-of-the-art mpMRI of the breast with T2-weighted, DCE-MRI and DWI from 12/2010 to 09/2014 and fulfilled the following inclusion criteria: 18 years or older; not pregnant; not breastfeeding; suspicious finding at mammography or breast ultrasonography, that is, asymmetric density, architectural distortion, breast mass, or microcalcifications (Breast Imaging Reporting and Data System [BI-RADS]: 0, further imaging warranted; 4, suspicious abnormality; 5, highly suggestive for malignancy); no previous treatment; and no contraindications for MRI or MRI contrast agents. Patients were excluded if there was no histopathologic verification of the imaging findings by either image-guided or surgical biopsy or if severe movement or susceptibility artifacts were seen on either DWI or DCE-MRI images. Based on a sample size calculation (refer to "Statistical Methods" section), 106 of 1119 patients were randomly selected using the selection criteria of lesion size 5 mm or bigger on DCE-MRI and a distribution of at least one-third benign breast tumors. In all patients, electronic medical records were reviewed and the following patient characteristics were recorded: age, pathology and in malignant lesions tumor grade, receptor status, and molecular subtype based on immunohistochemical surrogates. Nineteen patients examined in this study have been previously analyzed in a different context. 26 
Imaging
All patients underwent breast MRI in the prone position using a 3 T scanner (Tim Trio, Siemens, Erlangen, Germany) and a 4-channel breast coil (InVivo, Orlando, FL). A standardized MRI protocol was performed with the following sequences.
A For DCE-MRI until 12/2011, a hybrid DCE-MRI protocol was used. 27 The protocol consisted of 5 alternating sections of high-spatial and high-temporal resolution T1-weighted sequences. First, a highspatial-resolution, precontrast coronal T1-weighted turbo 3-dimensional (3D) fast low angle shot (FLASH) sequence without preparation pulse and with selective water excitation (TR/TE, 877/3.82 milliseconds; FOV, 320 mm; 96 slices; 1 mm isotropic; matrix, 320 Â 134; 1 average; bandwidth, 200 Hz/pixel; 2 minutes) was acquired. Subsequently, a coronal T1-weighted volume interpolated breathhold examination sequence (TR/TE, 3.61/1.4 millisecond; FOV, 320 mm; 72 slices; 1.7 mm isotropic; matrix, 192 Â 192; 1 average; bandwidth, 400 Hz/pixel; 13.2 seconds per volume) for the optimal assessment of the contrast-enhancement kinetics of lesions, was obtained. We performed 17 measurements including baseline scan as the peak enhancement of the lesion could be expected at the end of this time span. Thereafter, contrast-enhanced, highspatial-resolution T1-weighted images (repeated 3D-FLASH) for optimal image quality at expected maximum contrast were acquired. Finally, the high temporal resolution (repeated volume interpolated breathhold examination with 25 measurements, leading to an acquisition time of 5 minutes 35 seconds and repeated 3D-FLASH) for dynamic assessment of lesion washout and then high-spatial-resolution T1-weighted images and delayed contrast-enhanced lesion morphology were recorded. The total time of acquisition was 9 hours 20 minutes.
From 01/2012 onward, a transversal T1-weighted time-resolved angiography with stochastic trajectories was acquired (water excitation fat-saturation; TR/TE, 6.23/2.95 milliseconds; flip angle, 15°; FOV, 196 Â 330 mm 2 ; 144 slices; spatial resolution, 0.9 Â 0.9 Â 1 mm; temporal interpolation factor, 2; temporal resolution, 14 seconds; matrix, 384 Â 384; 1 average; center k-space region with a resampling rate of 23%; reacquisition density of peripheral k-space, 20%; and TA, 6 minutes and 49 seconds).
A standard dose (0.1 mmol/kg body weight) of gadoterate meglumine (Gd-DOTA; Dotarem, Guerbet, France) was injected intravenously as a bolus at 4 mL/s, with a saline flush after injection. Total MRI examination time was approximately 12 to 16 minutes. , 11 years of experience in breast MRI) independently evaluated DWI, DCE, and mpMRI. T2-weighted imaging was not used for analysis and b0 images of DWI were used to provide T2-weighted imaging contrast. Lesion location by clock position and depth per BI-RADS was recorded. Readers first assessed DWI alone blinded to the DCE-MRI. After the washout time period of at least 21 days, DCE-MRI alone was read. Consequently, the results of both readings were reviewed by R1 for missed lesion on DWI or a lesion mismatch between DCE-MRI and DWI. In case of mismatched lesions or lesions missed in DWI, the ADC values for these were measured. Finally, mpMRI results were derived using the algorithm described below. All readers were aware that all patients had a breast lesion but were not provided with conventional and previous imaging or histopathological results.
Image Analysis

Diffusion-Weighted Imaging
High-b-value (ie, 850 s/mm 2 ) images were qualitatively assessed for hyperintense regions. One 2D region of interest per lesion and per reader was drawn manually on ADC maps on the area with the lowest ADC values inside the lesions, 28 using OSIRIX software 29 and the mean ADC of lesions was determined. A previously published ADC cutoff value of 1.25 Â 10 −3 mm 2 /s was used to differentiate between benign and malignant lesions. 30 
Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Dynamic contrast-enhanced MRI was evaluated using the fifth edition MRI BI-RADS lexicon. 31 Size, location, type of enhancement (mass or nonmass enhancement [NME]), morphologic descriptors for masses and NME, and kinetics according to BI-RADS were recorded. For the kinetic curve assessment, an automated semiquantitative curvetype analysis was performed using the DCE Tool plugin v2.2 for OSIRIX. 29 Average lesion sizes are reported for R1. Examinations were classified as either definitively benign (no indication of malignancy) or abnormal (suspicious finding, histopathologic verification necessary) and a BI-RADS assessment category [1] [2] [3] [4] [5] was assigned.
Multiparametric MRI
Multiparametric MRI with DWI and DCE-MRI was evaluated using a previously published reading method where BI-RADS values are adapted using different ADC thresholds for different BI-RADS categories to account for the higher likelihood of malignancy in lesions with a higher BI-RADS assessment category. 25 The ADC thresholds for masses and NME for different BI-RADS categories are summarized in Table 1 . A final classification as either definitively benign or abnormal was given. If a BI-RADS 4 or 5 was assigned on DCE-MRI, a high ADC (>1.39 or >1.66 for masses and >1.28 or >1.62 for NMEs) ( Table 1 ) was required to assign a final classification as benign. If a BI-RADS 2 or 3 was assigned, a low ADC (<0.87 or <1.13 for masses and <0.62 or <0.95 for NMEs) ( Table 1 ) was required to assign a final classification as malignant.
Standard of Reference
Histopathology was used as the reference standard. Histopathologic diagnosis was established by 1 experienced pathologist (Z.B-H) using either image-guided needle biopsy or surgery. In case of a high-risk lesion (regarded as benign), the final diagnosis was established with surgery (n = 7). In lesions suspicious in DWI yet without any enhancement (n = 4: R1, n = 2; R2, n = 2, R3, n = 1; R4, n = 4), DCE-MRI overruled and was used as the gold standard.
Statistical Methods
Statistical analysis was performed by a statistician (M.W), using SPSS 24.0 (IBM Corp, Armonk, NY). All calculations were performed on a per-lesion basis. Clustering effects due to several lesions were not taken into account. To account for skewed data, lesion size was described using median and range. To calculate the sensitivity and specificity of DWI, DCE-MRI, and mpMRI of the breast, the assigned final MR BI-RADS classifications were dichotomized: BI-RADS 1, 2, and 3 were considered benign, and BI-RADS 4 and 5 were considered malignant. Sensitivity, specificity, accuracy, negative predictive value (NPV), positive predictive value (PPV), area under the curve (AUC), and 95% confidence intervals (CIs) for each parameter were calculated. Statistical differences between modalities and readers were assessed using general estimation equations. P ≤ 0.05 was considered significant. Interreader variability for nominal and ordinal parameters was assessed by Fleiss κ statistics.
A sample size calculation using Nquery Advisor 7.0 32 revealed that 102 cases are needed to obtain a power of 80% (alpha 5%, 2 sided) to detect the expected 7% difference in accuracy between DCE-MRI and DWI (given 8% discordant ratings).
RESULTS
Histopathological diagnoses are summarized in Table 2 . There were 69 malignant (median, 20 mm; range, 6-100 mm) and 41 benign (median, 16 mm; range, 8-100 mm) tumors in 106 patients (age: mean, 51.6 years; range, 21-86 years). Four patients presented with bilateral lesions. Sensitivity, specificity, PPV, NPV, diagnostic accuracy, AUC for DCE-MRI, DWI, and mpMRI for all readers, and means are summarized in Table 3 . Detailed histopathological results and lesions sizes of false-positives (FPs) and false-negatives (FNs) with DCE-MRI, DWI, and mpMRI are detailed in Table 4 .
Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Dynamic contrast-enhanced MRI was the most sensitive technique for breast cancer detection, with an average sensitivity of 100% with average NPV for breast cancer diagnosis of 99.9%. However, it had the greatest number of FPs, with 12 (R1), 9 (R2), 11 (R3), and 7 (R4).
Diffusion-Weighted Imaging
Diffusion-weighted imaging detected significantly fewer breast cancers compared with both DCE-MRI (P < 0.0001) as well as mpMRI (P < 0.0001), with 11 (R1), 11 (R2), 15 (R3), and 13 (R4) FNs (Figs. 1  and 2 ). Missed lesions with DWI were consistently 12 mm or smaller in size (Fig. 3) , except for 3 invasive lobular carcinomas (ILCs) (all readers: 25 mm; R4: 26, 75 mm) and 2 invasive ductal carcinomas (IDCs) presenting as diffuse NME (R3, 15 mm, 18 mm) and 2 mucinous carcinomas (all readers, 17 mm, 38 mm). Lesions 12 mm or smaller in size comprised both invasive and noninvasive disease, as well as all histopathological types (IDC, ILC, ductal carcinoma in situ [DCIS] , and mucinous) and tumor grades, with most being rather intermediate and high grade. The mean NPV of DWI (0.74) was significantly lower compared with that of DCE-MRI (0.99, P < 0.001) and mpMRI (0.94, P < 0.001). Therefore, DWI cannot be used as a stand-alone parameter for breast cancer detection in comparison with DCE-MRI or mpMRI.
Diffusion-weighted imaging was significantly more specific than DCE-MRI (P = 0.002) for lesion characterization, with an average specificity of 86.8%. The PPVof DWI was significantly higher, with an average of 91.2% compared with DCE-MRI, and yet was not significantly different from mpMRI (P = 0.815). Diffusion-weighted imaging would have obviated 50% (6/12) for R1, 33.3% (3/9) for R2, 63.6% (7/11) for R3, and 85.7% (6/7) for R4 of benign breast biopsies recommended with DCE-MRI alone.
Multiparametric MRI was significantly more sensitive than DWI and not significantly different from DCE-MRI (P = 0.120). Multiparametric MRI (P = 0.009) maintained the high specificity of DWI, with an average of 83.8% (P = 0.195), and was also more specific than DCE-MRI (P = 0.009) (Fig. 4) . The PPVof mpMRI was significantly higher compared with that of DCE-MRI (P = 0.022) and yet was not significantly different between DWI and mpMRI (P = 0.815). Multiparametric MRI would have obviated 33.3% (4/12) for R1, 33.3% (3/9) for R2, 27.3% (3/11) for R3, and 28.6% (2/7) for R4 of unnecessary breast biopsies recommended with DCE-MRI alone (Fig. 5) .
Diagnostic Accuracy
The receiving operator characteristic (ROC) curves for all readers and parameters are depicted in Figure 6 . The ROC analysis yielded the best AUC for mpMRI, compared with DCE-MRI and DWI alone (Table 3) . Modified from Pinker et al. 25 ADC indicates apparent diffusion coefficient; mp, multiparametric; MRI, magnetic resonance imaging; DCE, dynamic contrast enhanced; DWI, diffusionweighted imaging; BI-RADS, Breast Imaging Reporting and Data System; NME, nonmass enhancement. The average diagnostic accuracy of mpMRI (91.9%) was higher than that of DCE-MRI (90.6%); although this did not reach statistical significance (P = 0.466), both mpMRI (P = 0.023) and DCE-MRI (P = 0.002) were significantly better than DWI, with an average accuracy of 83.7%.
Intrareader and Interreader Agreement
There was almost perfect interreader agreement for both DWI (benign vs. malignant), with κ = 0.864, and for DCE-MRI (benign vs malignant), with κ = 0.875, and there was moderate interrater agreement for the assigned BI-RADS assessment category, with κ = 0.57.
There was no significant moderation of readers on parameters effects for either sensitivity (P = 0.072), specificity (P = 0.365), PPV (P = 0.573), NPV (P = 0.693), or diagnostic accuracy (P = 0.750).
DISCUSSION
The DCE-MRI detects significantly more cancers than DWI does (P < 0.0001), with sensitivities decreasing especially in lesions 12 mm or smaller or presenting as diffuse NME. Therefore, DWI cannot be used as a stand-alone parameter for breast cancer detection. Multiparametric MRI combining DWI and DCE-MRI achieves high sensitivity and specificity, maximizing diagnostic accuracy and therefore obviating unnecessary breast biopsies in up to one-third of benign breast findings.
In this study, DCE-MRI achieved the highest sensitivity for breast cancer detection for all readers, ranging from 99% to 100%. This supports recent previous results that DCE-MRI is still superior to unenhanced MRI with or without supportive sequences. 33 In addition, the results are in good agreement with the existing body of evidence that DCE-MRI is the most sensitive test for breast cancer detection and outperforms conventional imaging methods in women, both with high and average risk of breast cancer. 1, [34] [35] [36] Yet this excellent sensitivity comes at the expense of decreased specificity because of the also increased detection of benign lesions and a significant overlap of DCE-MRI features of benign and malignant lesions. This limitation causes unnecessary benign breast biopsies, patient anxiety, and costs to the health care system. Meanwhile, DWI is emerging as a robust, sensitive, and especially specific tool for unenhanced breast MRI. 5, 6, 8 However, in most previous studies, a high-resolution sequence to identify the breast lesion was a prerequisite for DWI interpretation, usually DCE-MRI, 6, 8, 9, 22, 23, 30 and incidentally T2-weighted or T1-weighted unenhanced images. 14, 17, 20 Thus, it was not assumed that the lesion could be identified directly on the DWI images. In our study, we found DWI detected significantly fewer cancers than DCE-MRI did (P < 0.0001), confirming that, currently, DWI cannot be used as a replacement for DCE-MRI in breast cancer detection. Sensitivity is decreased in mass lesions 12 mm or smaller regardless of invasiveness, histopathological type, and grade and those presenting as diffuse NME regardless of size. It therefore appears the spatial resolution of DWI is still too low to be used alone for early detection. Current routine DCE-MRI easily achieves a spatial resolution of down to 1 mm isotropic at 3 T or even less at 7 T, 37 thereby reliably detecting these challenging lesions. On the other hand, the limited spatial resolution of DWI is therefore especially concerning in use for screening as the goal is early detection when lesions are still small and not yet metastasized. 38 Research to improve spatial resolution of DWI is ongoing, and there have been significant improvements in spatial resolution with the introduction of read-out segmented echo-planar imaging sequences. 9 Therefore, it can be expected that further advances are possible, and in the future, DWI may be able to overcome its current limitations. In addition, other advanced DWI techniques such intravoxel incoherent motion, diffusion kurtosis imaging, and diffusion tensor imaging are under investigation for their eventual role in breast imaging. [39] [40] [41] [42] Initial results indicate that there is potential to add further specificity to DCE, yet the clinical value of these additional techniques remains to be proven.
In our study, mpMRI achieved the highest diagnostic accuracy for all readers, from 91% to 93%. Multiparametric MRI obviates unnecessary breast biopsies in up to 33.3%, whereas the sensitivity for breast cancer is not significantly different from DCE-MRI, which is imperative. Multiparametric MRI is significantly more specific than DCE-MRI alone, and this study underscores the necessity of combining DCE-MRI and DWI in a multiparametric imaging concept, which counterbalances the lack of sensitivity of DWI and the lack of specificity of DCE-MRI. Our results are in agreement with others who investigated mpMRI using different approaches to combine DWI and DCE-MRI and have demonstrated that mpMRI improves diagnostic accuracy. [22] [23] [24] Although DCE-MRI is the backbone of any given imaging protocol, the recent controversy about the safety of gadolinium-containing contrast agents 3 and the recommendation to use gadolinium contrast agents only when essential diagnostic information cannot be obtained with unenhanced scans make the results of the current study particularly relevant. 4 Our data indicate that for time being, DWI with ADC mapping currently cannot be used as a stand-alone parameter for breast cancer detection yet, but as a complementary tool to DCE-MRI in a multiparametric MRI protocol to ensure breast cancer detection while decreasing unnecessary biopsies.
Although FPs were consistently reduced with mpMRI (27.3-33.3%), some remained. These were composed of up to 4 FP high-risk lesions that, per definition, have an uncertain potential for malignancy. 43 The decreased ADC values encountered in these FPs might reflect this potential or even an impending malignant transformation. Two FPs were clinically asymptomatic chronic abscesses, 1 fat necrosis and 1 fibrochystic changes, where ADCs might be decreased owing to extensive fibrotic components. There were also some FN lesions with mpMRI. One FN was a mucinous carcinoma, which is known to present with very high ADC values owing to its mucinous content. 44 The other FNs comprised a small IDC and a DCIS presenting as NME with borderline ADC values. There was almost perfect interreader agreement for both DWI (benign vs malignant) and DCE-MRI (benign vs malignant). Readers were experienced breast radiologists with extensive training in breast MRI. Therefore, the results might not be applicable to every radiologist. However, our results are in good agreement with previous published data on high-resolution DCE-MRI and DWI. 9, 30, 37 Our study is limited by the relatively small number of pure DCIS and ILC compared with the number of invasive ductal cancers, which limits specific insights into the performance of mpMRI in these subgroups. Nevertheless, the excellent results of mpMRI for both ILC and DCIS are in good agreement with previously published data at 1.5 and 3 T 25,37 and therefore underline the potential of mpMRI when compared with DCE-MRI and DWI alone. It should be mentioned that as our institution is a referral center, this was an enriched cohort with all patients presenting with 1 (n = 106) or 2 (n = 4) lesions.
To date, DWI cannot be used as a stand-alone parameter for breast cancer detection, with sensitivities decreased in smaller cancers and those presenting as diffuse NME in comparison with DCE-MRI and mpMRI. Dynamic contrast-enhanced MRI remains the most sensitive test for breast cancer detection and thus is still indispensable. Multiparametric MRI performed as the combination of DCE-MRI and DWI achieves both high sensitivity and specificity and should therefore be implemented into the standard MRI protocol to maximize diagnostic accuracy while decreasing unnecessary breast biopsies. . DCE-MRI and DWI were discordant. According to the BI-RADS-adapted reading algorithm, the BI-RADS assessment category assigned based on DCE-MRI was overruled and multiparametric MRI correctly classified the mass as benign.
FIGURE 6. ROC analysis for all readers and parameters. The ROC curves illustrate the higher diagnostic value (ie, higher sensitivity, specificity, and larger AUC) that was reached for mpMRI using the BI-RADS-adapted reading method, compared with DCE-MRI and DWI alone for all readers.
